Author: Ying Huang; Rui Yang; Ying Xu; Ping Gong
                    Title: Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China  Document date: 2020_2_29
                    ID: 9hh17k86_45
                    
                    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.27.20029009 doi: medRxiv preprint the increased CRP, PCT concentration and decreased lymphocyte count from admission to death (Supplementary Figure 2) , which may represent more prominent inflammation in severe patients. Therefore, intravenous glucocorticoids therapy, intravenous immunoglobulin therapy and interferon-alpha (α-IFN) aeroso.....
                    
                    
                    
                     
                    
                    
                    
                    
                        
                            
                                Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.02.27.20029009 doi: medRxiv preprint the increased CRP, PCT concentration and decreased lymphocyte count from admission to death (Supplementary Figure 2) , which may represent more prominent inflammation in severe patients. Therefore, intravenous glucocorticoids therapy, intravenous immunoglobulin therapy and interferon-alpha (α-IFN) aerosol inhalation were also used to restore homeostasis, without solid evidence. To our knowledge, there is still no specific medicine for COVID-19 till now. Clinical trials on promising regimens for COVID-19, such as remdesivir, lopinavir, and chloroquine phosphate are ongoing, which shed light on conquering the COVID-19 epidemic 12 .
 
  Search related documents: 
                                Co phrase  search for related documents- aerosol inhalation and clinical trial: 1, 2, 3, 4, 5
  - aerosol inhalation and immunoglobulin therapy: 1
  - aerosol inhalation and lymphocyte count: 1
  - aerosol inhalation and severe patient: 1
  - chloroquine phosphate and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
  - chloroquine phosphate and severe patient: 1
  - chloroquine phosphate and specific medicine: 1, 2
  - clinical trial and glucocorticoid therapy: 1, 2, 3, 4, 5, 6
  - clinical trial and homeostasis restore: 1
  - clinical trial and immunoglobulin therapy: 1, 2, 3, 4, 5, 6, 7
  - clinical trial and increase crp: 1, 2, 3, 4
  - clinical trial and intravenous immunoglobulin therapy: 1, 2, 3
  - clinical trial and light shed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
  - clinical trial and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
  - clinical trial and pct concentration: 1
  - clinical trial and prominent inflammation: 1
  - clinical trial and promise clinical trial: 1, 2, 3, 4, 5
  - clinical trial and severe patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
  - clinical trial and solid evidence: 1, 2, 3, 4, 5, 6, 7, 8
  
 
                                Co phrase  search for related documents, hyperlinks ordered by date